SCHEMBL2657441

SCHEMBL2657441

Cc1ccc(C(=O)Nc2nccs2)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 15/20 1.00
RAB9A P51151 15/20 1.00
KMT2A Q03164 7/20 0.69
MEN1 O00255 6/20 0.69
ALDH1A1 P00352 5/20 0.69
HPGD P15428 2/20 0.69
SMN1; SMN2 Q16637 3/20 0.60
PPARG P37231 1/20 0.60
NCOR2 Q9Y618 1/20 0.60
L3MBTL1 Q9Y468 4/20 0.56
LMNA P02545 4/20 0.56
KDM4E B2RXH2 2/20 0.56
MAPT P10636 2/20 0.56
HTT P42858 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
METAP2 P50579 1/20 0.54
METAP1 P53582 1/20 0.54
POLB P06746 1/20 0.54
BLM P54132 1/20 0.54
TDP1 Q9NUW8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12124195 0.77 NPC1 (0.62) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL17644750 0.77 RAB9A (0.62) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2658062 0.76 NPC1 (0.66) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2656790 0.76 NPC1 (0.61) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL27924845 0.75 NPC1 (1.00) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL3223685 0.75 RAB9A (1.00) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL12195617 0.75 NPC1 (0.67) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2140334 0.75 NPC1 (0.59) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL16073043 0.74 NPC1 (0.66) NPC1RAB9AKMT2AALDH1A1HPGD
SCHEMBL12124292 0.73 NPC1 (0.57) NPC1RAB9AKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2244706-B1 GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2016-04-06 EP claimed
CN-101959515-B Glucokinase activators MERCK PATENT GMBH 2013-06-12 CN claimed
CN-101959515-A Glucokinase activators MERCK PATENT GMBH 2011-01-26 CN claimed
US-20100331338-A1 Glucokinase Activators MERCK PATENT GMBH (DE) 2010-12-30 US claimed
EP-2244706-A1 GLUCOKINASE ACTIVATORS Merck Patent GmbH (DE) 2010-11-03 EP claimed
WO-2009106203-A1 GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2009-09-03 WO claimed
US-20210371416-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2021-12-02 US disclosed
US-9815831-B2 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-11-14 US disclosed
US-20170240542-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2017-08-24 US disclosed
EP-2244706-B1 GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2016-04-06 EP disclosed
US-20150133449-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2015-05-14 US disclosed
US-20150057309-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC RHIZEN PHARMACEUTICALS AG (CH) 2015-02-26 US disclosed
US-8912331-B2 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-12-16 US disclosed
US-20110281865-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2011-11-17 US disclosed
CN-101959515-A Glucokinase activators MERCK PATENT GMBH 2011-01-26 CN disclosed
US-20100331338-A1 Glucokinase Activators MERCK PATENT GMBH (DE) 2010-12-30 US disclosed
US-20100331338-A1 Glucokinase Activators MERCK PATENT GMBH (DE) 2010-12-30 US disclosed
EP-2244706-A1 GLUCOKINASE ACTIVATORS Merck Patent GmbH (DE) 2010-11-03 EP disclosed
WO-2009106203-A1 GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2009-09-03 WO disclosed
WO-2009106203-A1 GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281865-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES MAP4K2, MAP4K3, MAP3K1 NPC1 2744/4885RAB9A 1446/4885KMT2A 2734/4885
US-20150133449-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES MAP4K2, MAP4K3, MAP3K1 NPC1 2744/4885RAB9A 1446/4885KMT2A 2734/4885
US-20100331338-A1 Glucokinase Activators GCKR, HK1, GCK NPC1 1277/4885RAB9A 2651/4885KMT2A 3253/4885
US-20150057309-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC MET, HGFAC, PRKCH NPC1 2080/4885RAB9A 2297/4885KMT2A 2706/4885
US-20210371416-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES MET, PRKCH, PRKCE NPC1 2634/4885RAB9A 2233/4885KMT2A 1859/4885
US-20170240542-A1 NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES MAP4K2, MAP4K3, MAP3K1 NPC1 2744/4885RAB9A 1446/4885KMT2A 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.